Jerome Edelson1, Alejandro L Suarez1, Jingwen Zhang2, Don C Rockey3. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 803, Charleston, SC, 29425, USA. 2. Division of General Internal Medicine, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. 3. Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 803, Charleston, SC, 29425, USA. rockey@musc.edu.
Abstract
BACKGROUND: Sedation during endoscopy in cirrhotic patients is typically via moderate sedation, most commonly using a combination of a benzodiazepine (i.e., midazolam) and narcotic (i.e., fentanyl) or with propofol using monitored anesthesia care (MAC). Here, we examined the safety of moderate sedation and MAC in patients with cirrhosis. METHODS: This retrospective cohort study of cirrhotic patients undergoing endoscopy from a large academic medical center between 2010 and 2014 examined extensive clinical data including the following: past history, physical findings, laboratory results, and procedural adverse events. Adverse events were defined a priori and included hypoxia, hypotension, bleeding, and death. RESULTS: We identified 2618 patients with cirrhosis who underwent endoscopic procedures; the mean age was 56 years, 36% were female, the mean Child-Pugh score was 9.3 (IQR: 8, 11), and Charlson Comorbidity Index score was 3.2 (IQR: 1, 4); 1157 had MAC; and 1461 had moderate sedation. There was no difference in the frequency of adverse events in MAC and moderate sedation groups, with a total of 15 adverse events (7/1157 MAC and 8/1461 moderate sedation). The most common procedure performed was esophagogastroduodenoscopy (EGD, n = 1667) and was associated with 10 adverse events. Overall, adverse events included bradycardia (1), hypoxia (7), bleeding (5), laryngospasm (1), and perforation (1). The frequency was similar for EGD, ERCP, and colonoscopy-each at a rate of 0.6%. CONCLUSIONS: Adverse events in cirrhotic patients undergoing endoscopy appeared to be similar with moderate sedation or MAC, and the frequency was the same for different types of procedures.
BACKGROUND: Sedation during endoscopy in cirrhoticpatients is typically via moderate sedation, most commonly using a combination of a benzodiazepine (i.e., midazolam) and narcotic (i.e., fentanyl) or with propofol using monitored anesthesia care (MAC). Here, we examined the safety of moderate sedation and MAC in patients with cirrhosis. METHODS: This retrospective cohort study of cirrhoticpatients undergoing endoscopy from a large academic medical center between 2010 and 2014 examined extensive clinical data including the following: past history, physical findings, laboratory results, and procedural adverse events. Adverse events were defined a priori and included hypoxia, hypotension, bleeding, and death. RESULTS: We identified 2618 patients with cirrhosis who underwent endoscopic procedures; the mean age was 56 years, 36% were female, the mean Child-Pugh score was 9.3 (IQR: 8, 11), and Charlson Comorbidity Index score was 3.2 (IQR: 1, 4); 1157 had MAC; and 1461 had moderate sedation. There was no difference in the frequency of adverse events in MAC and moderate sedation groups, with a total of 15 adverse events (7/1157 MAC and 8/1461 moderate sedation). The most common procedure performed was esophagogastroduodenoscopy (EGD, n = 1667) and was associated with 10 adverse events. Overall, adverse events included bradycardia (1), hypoxia (7), bleeding (5), laryngospasm (1), and perforation (1). The frequency was similar for EGD, ERCP, and colonoscopy-each at a rate of 0.6%. CONCLUSIONS: Adverse events in cirrhoticpatients undergoing endoscopy appeared to be similar with moderate sedation or MAC, and the frequency was the same for different types of procedures.
Entities:
Keywords:
Adverse events; Colonoscopy; Esophagogastroduodenoscopy; Moderate sedation; Monitored anesthesia care
Authors: John J Vargo; Paul J Niklewski; J Lucas Williams; James F Martin; Douglas O Faigel Journal: Gastrointest Endosc Date: 2016-02-18 Impact factor: 9.427
Authors: Peter B Cotton; Glenn M Eisen; Lars Aabakken; Todd H Baron; Matt M Hutter; Brian C Jacobson; Klaus Mergener; Albert Nemcek; Bret T Petersen; John L Petrini; Irving M Pike; Linda Rabeneck; Joseph Romagnuolo; John J Vargo Journal: Gastrointest Endosc Date: 2010-03 Impact factor: 9.427
Authors: Dayna S Early; Jenifer R Lightdale; John J Vargo; Ruben D Acosta; Vinay Chandrasekhara; Krishnavel V Chathadi; John A Evans; Deborah A Fisher; Lisa Fonkalsrud; Joo Ha Hwang; Mouen A Khashab; V Raman Muthusamy; Shabana F Pasha; John R Saltzman; Amandeep K Shergill; Brooks D Cash; John M DeWitt Journal: Gastrointest Endosc Date: 2018-01-03 Impact factor: 9.427
Authors: Lawrence B Cohen; Julie S Wecsler; John N Gaetano; Ariel A Benson; Kenneth M Miller; Valerie Durkalski; James Aisenberg Journal: Am J Gastroenterol Date: 2006-05 Impact factor: 10.864
Authors: David A Lubarsky; Jason R Guercio; John W Hanna; Maria T Abreu; Qianli Ma; Claudia Uribe; David J Birnbach; David R Sinclair; Keith A Candiotti Journal: J Multidiscip Healthc Date: 2015-05-28